GlassScriptPhysician profile
Julian Map Ngo
NPI 1689989675
$5,116.92
in general payments reported to CMS, 2019-2025
24 companies · $868 in 2025
The $868 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $376 · 2021: $674 · 2022: $632 · 2023: $873 · 2024: $911 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138 · Education: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.74 |
| Education | $513.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.41 | 2019-2025 | |
| Janssen Biotech, INC. | $672.66 | 2019-2025 | Tremfya |
| Pfizer INC. | $438.90 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $434.82 | 2019-2025 | Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $349.55 | 2019-2025 | |
| Ucb, INC. | $348.38 | 2022-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $330.83 | 2019-2025 | Dupixent |
| Genzyme Corporation | $280.94 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $280.23 | 2019-2021 | |
| Amgen INC. | $216.43 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $172.81 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $171.76 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $101.98 | 2021-2025 | Adbry |
| Lilly USA, LLC | $69.77 | 2019-2023 | Olumiant, Taltz |
| Dermavant Sciences, INC. | $37.80 | 2023 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.16 | 2025 | Spevigo |
| Celgene Corporation | $33.45 | 2019 | |
| Dusa Pharmaceuticals, INC. | $31.29 | 2019 | |
| Mayne Pharma Commercial LLC | $23.31 | 2020 | |
| Dermira, INC. | $21.24 | 2019 | |
| Journey Medical Corporation | $18.69 | 2019 | |
| Organogenesis INC. | $18.63 | 2019 | |
| Fresenius Kabi USA, LLC | $17.10 | 2025 | Idacio |
| Genentech USA, INC. | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.